Department of Pharmacy, Jiangxi Provincial Children's Hospital, Nanchang, P.R., China.
Department of Pharmacy, Jiangxi Provincial Children's Hospital, Nanchang, P.R., China.
Diagn Microbiol Infect Dis. 2023 Aug;106(4):115956. doi: 10.1016/j.diagmicrobio.2023.115956. Epub 2023 Apr 20.
Antibiotic resistance surveillance may be essential to identify patterns of antibiotic resistance and guide treatment choices. Therefore, this systematic review and meta-analysis aimed to evaluate amikacin resistance and susceptibility in children with extended-spectrum beta-lactamase-producing Enterobacterales (ESBL-PE). From inception to September 5, 2022, relevant studies were searched via PubMed, Embase, Cochrane Library, and Web of Science databases. A network meta-analysis was conducted to explore the sequencing of resistance rates in amikacin and other antibiotics. Totally, 26 studies with 2582 clusters of bacterial isolates were included. The resistance rate of amikacin in children with ESBL-PE was 10.1%, higher than the resistance rate of tigecycline (0.0%), ertapenem (0.4%), meropenem (0.7%), and imipenem (3.0%). For the drug susceptibility rate in children with ESBL-PE, the susceptibility rate of amikacin (89.7%) was lower than tigecycline (99.6%), imipenem (96.8%), meropenem (97.3%), and ertapenem (95.6%). Amikacin showed a low drug resistance and a high drug resistance in children with ESBL-PE infection, making it a good option for the treatment of the infection caused by ESBL-PE.
抗生素耐药性监测对于识别抗生素耐药模式和指导治疗选择可能至关重要。因此，本系统评价和荟萃分析旨在评估产超广谱β-内酰胺酶肠杆菌科（ESBL-PE）儿童中阿米卡星的耐药性和敏感性。从开始到 2022 年 9 月 5 日，通过 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库搜索相关研究。进行了网络荟萃分析，以探讨阿米卡星和其他抗生素耐药率的顺序。共纳入 26 项研究，包含 2582 个细菌分离株簇。ESBL-PE 患儿中阿米卡星的耐药率为 10.1%，高于替加环素（0.0%）、厄他培南（0.4%）、美罗培南（0.7%）和亚胺培南（3.0%）。对于 ESBL-PE 患儿的药物敏感性率，阿米卡星（89.7%）的敏感性率低于替加环素（99.6%）、亚胺培南（96.8%）、美罗培南（97.3%）和厄他培南（95.6%）。阿米卡星在 ESBL-PE 感染儿童中表现出低耐药性和高耐药性，使其成为治疗 ESBL-PE 引起的感染的良好选择。
